First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors
Open accessPublished version of a preprint
The DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Purpose: A first-in-human phase I study was conducted to characterize safety, efficacy, and pharmacokinetic (PK) and pharmacodynamic (PD) properties of lumretuzumab, a humanized and glycoengineered anti-HER3 monoclonal antibody, in patients with advanced cancer. Experimental Design: Twenty-five patients with histologically confirmed HER3-expressing tumors received lumretuzumab (100, 200, 400, 800, 1,600, and 2,000 mg) every two weeks (q2w) in 3+3 dose-escalation phase. In addition, 22 patients were enrolled into an extension cohort at 2,000 mg q2w. Results: There were no dose-limiting toxicities. Common adverse events (any grade) included diarrhea (22 patients, 46.8%), fatigue (21 patients, 44.7%), decreased appetite (15 patients, 31.9%), infusion-related reactions (13 patients, 27.7%), and constipation (10 patients, 21.3%). The peak concentration (Cmax) and area under the concentration–time curve up to the last measurable concentration (AUClast) of lumretuzumab increased more than dose proportionally from 100 mg up to 400 mg. Linear PK was observed with doses ≥400 mg q2w indicating target-mediated drug disposition saturation. Downregulation of HER3 membranous protein was observed in on-treatment tumor biopsies from 200 mg, and was maximal at and above 400 mg. An ex vivo assay demonstrated increased activation potential of peripheral NK lymphocytes with lumretuzumab compared with a non-glycoengineered anti-HER3 antibody. Ten patients (21.3%) had stable disease and remained on study at a median of 111 days (range, 80–225 days). Conclusions: Lumretuzumab was well tolerated and showed evidence of clinical activity. Linear serum PK properties and plateauing of PD effects in serial tumor biopsies indicate optimal biologically active doses of lumretuzumab from 400 mg onwards. Clin Cancer Res; 22(4); 877–85. ©2015 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Currently, HER3-targeted drugs U3-1402 [30], lumretuzumab [76] and MEHD7945A [77] have been used in preclinical and clinical trials with good safety and efficacy.”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [76]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 33 · Cited by 73
Research works printed but not linked: 1
- van Pawel, 2014, Phase 2 HERALD study of patritumab with erlotinib in advanced NSCLC subjects, J Clin Oncol, 32
Metadata
- Authors
- Meulendijks, D., Jacob, W., Martinez-Garcia, M., Taus, A., Lolkema, M. P., Voest, E. E., Langenberg, M. H. G., Fleitas Kanonnikoff, T., Cervantes, A., De Jonge, M. J., Sleijfer, S., Soerensen, M. M., Thomas, M., Ceppi, M., Meneses-Lorente, G., James, I., Adessi, C., Michielin, F., Abiraj, K., Bossenmaier, B., Schellens, J. H. M., Weisser, M., & Lassen, U. N.
- Affiliations
- The Netherlands Cancer Institute (NL)
- 2Pharma Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.
- 3Department of Medical Oncology, Hospital del Mar, Barcelona, Spain.
- Erasmus MC (NL)
- University Medical Center Utrecht (NL)
- 6Department of Hematology and Medical Oncology, Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain.
- 5Department of Medical Oncology, Erasmus Medical Center Cancer Institute and Cancer Genomics, Rotterdam, the Netherlands.
- 7Department of Oncology, Rigshospitalet, Copenhagen, Denmark.
- 8Pharma Research and Early Development, Roche Innovation Center Welwyn, Welwyn, United Kingdom.
- 9Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
- F. Hoffmann-La Roche AG (CH)
- Rigshospitalet (DK)
- Corresponding author
- Jacob, Wolfgang
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2016-02-14
- Volume
- 22
- Issue
- 4
- Pages
- 877-885
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2178676862
- Cited by
- 73
- References
- 33
- Citations by year
- 2025: 4 · 2024: 4 · 2023: 14 · 2022: 8 · 2021: 6 · 2020: 4 · 2019: 7 · 2018: 12 · 2017: 8 · 2016: 5
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- green
- dspace.library.uu.nl
- Licence
- other-oa
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- Funders
- F. Hoffmann-La Roche
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- anti-HER3 monoclonal antibody, metastatic cancer, glycoengineering, humanized monoclonal antibody, dose escalation, pharmacokinetics, pharmacodynamics, target-mediated drug disposition, NK cell activation, safety and tolerability, first-in-human
- MeSH terms
- Adult, Aged, Analgesics, Female, Humans, Male, Middle Aged, Colorectal Neoplasms, Treatment Outcome, Maximum Tolerated Dose, Receptor, ErbB-3, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-1683
- The paper
- Meulendijks, D., Jacob, W., Martinez-Garcia, M., Taus, A., Lolkema, M. P., Voest, E. E., Langenberg, M. H. G., Fleitas Kanonnikoff, T., Cervantes, A., De Jonge, M. J., Sleijfer, S., Soerensen, M. M., Thomas, M., Ceppi, M., Meneses-Lorente, G., James, I., Adessi, C., Michielin, F., Abiraj, K., . . . Lassen, U. N. (2016). First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-1683
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.